N- (2- fluoro- 4- ((2- (4- (4- methylpiperazin- 1- yl)piperidin- 1- yl)carbonylaminopyridin- 4- yl)oxy)phenyl)- N'- (4- fluorophenyl)cyclopropane- 1,1- dicarboxamide

12/15/2014 - "Patients with advanced solid tumors received golvatinib orally, once daily, continuously. "
12/15/2014 - "A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors."
02/01/2015 - "Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model."
06/01/2014 - "xenograft models based on various tumor cell lines with high HGF expression, treatment with lenvatinib alone showed weak antitumor effects, but treatment with lenvatinib plus golvatinib showed synergistic antitumor effects, accompanied by decreased tumor vessel density. "
07/01/2017 - "Furthermore, treatment with either crizotinib or golvatinib suppressed the systemic metastasis of SBC-5 cell tumors in natural killer cell-depleted SCID mice, predominantly through cell cycle arrest. "

01/01/2020 - "Considering the difference in the effects of golvatinib on immortalized tubular epithelial cells among patients, this analysis may aid in selecting suitable drugs for individual ADPKD patients."

02/01/2015 - "In thyroid and endometrial cancer models, golvatinib and lenvatinib inhibited pericyte network development and TEM infiltration, resulting in severe perfusion disorder and massive apoptosis. "

07/01/2017 - "Furthermore, treatment with either crizotinib or golvatinib suppressed the systemic metastasis of SBC-5 cell tumors in natural killer cell-depleted SCID mice, predominantly through cell cycle arrest. "

01/01/2019 - "Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 μM. "